Brit J Surg:年轻直肠癌患者的临床病理特征和肿瘤学结局

2020-03-11 MedSci原创 MedSci原创

尽管获得更多的治疗,但年轻患者的疾病特异性结局与老年患者相当。

年龄小于50岁的成年人中直肠癌的发病率正在上升。生存数据有限且相互矛盾,并且标准的新辅助药和辅助疗法的肿瘤学益处尚不清楚。

近日,外科疾病领域权威杂志British Journal of Surgery上发表了一篇研究文章,研究人员分析了2006年至2016年期间诊断的接受手术切除的直肠癌患者特定疾病结局。

该研究总确定了797例直肠癌患者,其中685例患者接受了根治性手术。年龄在50岁以下的患者有70人,年龄在50岁以上的患者有615人。两个年龄组的临床分期无显著差异。年龄小于50岁的患者更有可能出现微卫星不稳定性(9% vs. 1.6%;P=0.003)和Lynch综合征(7% vs. 0%;P<0.001)。年轻患者也更有可能接受新辅助放化疗(67 vs. 53.3%;P=0.003)和辅助化学疗法(41 vs. 24.2%;P=0.006)。在50岁以下的人群中,五年总体生存率更高(80% vs. 72%;P=0.013)。两个年龄组的5年无病生存率均为81%(P=0.711)。局部复发或远处转移的发生没有显著差异。

尽管获得更多的治疗,但年轻患者的疾病特异性结局与老年患者相当。

原始出处:

A. M. Zaborowski.Clinicopathological features and oncological outcomes of patients with young‐onset rectal cancer.British Journal of Surgery.2020.https://doi.org/10.1002/bjs.11526

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1797478, encodeId=59e81e97478af, content=<a href='/topic/show?id=96eb22906b9' target=_blank style='color:#2F92EE;'>#临床病理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22906, encryptionId=96eb22906b9, topicName=临床病理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Sep 17 01:39:43 CST 2020, time=2020-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033196, encodeId=695e2033196d9, content=<a href='/topic/show?id=c097e104497' target=_blank style='color:#2F92EE;'>#病理特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71044, encryptionId=c097e104497, topicName=病理特征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Thu Apr 02 23:39:43 CST 2020, time=2020-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1390801, encodeId=e0c9139080171, content=<a href='/topic/show?id=8eeb828963a' target=_blank style='color:#2F92EE;'>#肿瘤学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82896, encryptionId=8eeb828963a, topicName=肿瘤学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Fri Mar 13 05:39:43 CST 2020, time=2020-03-13, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1797478, encodeId=59e81e97478af, content=<a href='/topic/show?id=96eb22906b9' target=_blank style='color:#2F92EE;'>#临床病理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22906, encryptionId=96eb22906b9, topicName=临床病理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Sep 17 01:39:43 CST 2020, time=2020-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033196, encodeId=695e2033196d9, content=<a href='/topic/show?id=c097e104497' target=_blank style='color:#2F92EE;'>#病理特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71044, encryptionId=c097e104497, topicName=病理特征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Thu Apr 02 23:39:43 CST 2020, time=2020-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1390801, encodeId=e0c9139080171, content=<a href='/topic/show?id=8eeb828963a' target=_blank style='color:#2F92EE;'>#肿瘤学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82896, encryptionId=8eeb828963a, topicName=肿瘤学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Fri Mar 13 05:39:43 CST 2020, time=2020-03-13, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1797478, encodeId=59e81e97478af, content=<a href='/topic/show?id=96eb22906b9' target=_blank style='color:#2F92EE;'>#临床病理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22906, encryptionId=96eb22906b9, topicName=临床病理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Sep 17 01:39:43 CST 2020, time=2020-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033196, encodeId=695e2033196d9, content=<a href='/topic/show?id=c097e104497' target=_blank style='color:#2F92EE;'>#病理特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71044, encryptionId=c097e104497, topicName=病理特征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Thu Apr 02 23:39:43 CST 2020, time=2020-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1390801, encodeId=e0c9139080171, content=<a href='/topic/show?id=8eeb828963a' target=_blank style='color:#2F92EE;'>#肿瘤学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82896, encryptionId=8eeb828963a, topicName=肿瘤学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Fri Mar 13 05:39:43 CST 2020, time=2020-03-13, status=1, ipAttribution=)]